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OBJECTIVE—Human adenovirus type 36 (Ad-36) increases
adiposity but improves insulin sensitivity in experimentally in-
fected animals. We determined the ability of Ad-36 to increase
glucose uptake by human primary skeletal muscle (HSKM) cells.
RESEARCH DESIGN AND METHODS—The effect of Ad-36
on glucose uptake and cell signaling was determined in HSKM
cells obtained from type 2 diabetic and healthy lean subjects.
Ad-2, another human adenovirus, was used as a negative control.
Gene expression and proteins of GLUT1 and GLUT4 were
measured by real-time PCR and Western blotting. Role of insulin
and Ras signaling pathways was determined in Ad-36–infected
HSKM cells.
RESULTS—Ad-36 and Ad-2 infections were conﬁrmed by the
presence of respective viral mRNA and protein expressions. In a
dose-dependent manner, Ad-36 signiﬁcantly increased glucose
uptake in diabetic and nondiabetic HSKM cells. Ad-36 increased
gene expression and protein abundance of GLUT1 and GLUT4,
GLUT4 translocation to plasma membrane, and phosphatidylino-
sitol 3-kinase (PI 3-kinase) activity in an insulin-independent
manner. In fact, Ad-36 decreased insulin receptor substrate-1
(IRS-1) tyrosine phosphorylation and IRS-1– and IRS-2–associ-
ated PI 3-kinase activities. On the other hand, Ad-36 increased
Ras gene expression and protein abundance, and Ras siRNA
abrogated Ad-36–induced PI 3-kinase activation, GLUT4 protein
abundance, and glucose uptake. These effects were not observed
with Ad-2 infection.
CONCLUSIONS—Ad-36 infection increases glucose uptake in
HSKM cells via Ras-activated PI 3-kinase pathway in an insulin-
independent manner. These ﬁndings may provide impetus to
exploit the role of Ad-36 proteins as novel therapeutic targets for
improving glucose handling. Diabetes 57:1805–1813, 2008
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ncreasing prevalence of type 2 diabetes and insulin
resistance is a major health and economic concern
(1,2) and necessitates more effective prevention and
treatment strategies. Intense search for identifying
novel agents that may provide therapeutic targets for better
management of diabetes is underway (3,4). Human adenovi-
rus Ad-36 is such a novel candidate that increases adiposity
but enhances insulin sensitivity in experimentally infected
rats (5), an effect that is robust and reminiscent of the
thiozolinediones (6,7). After a single inoculation of Ad-36, fat
depot weight increased by 60%, but the fasting insulin
levels and homeostasis model assessment (HOMA) index
were 50% lower in rats up to 7 months later (5). Therefore,
we postulated that Ad-36 increases glucose uptake in in-
fected tissue, which may contribute in enhancing whole-body
insulin sensitivity.
This study investigated the ability of Ad-36 to enhance
glucose uptake by skeletal muscle. Skeletal muscle is the
largest organ of the human body and is a major site of
glucose disposal and insulin action (8). Therefore, exploit-
ing the ability of Ad-36 to enhance glucose uptake by
skeletal muscle may provide a novel therapeutic target to
treat glycemic disregulation in humans.
In a stepwise approach, we investigated how Ad-36
inﬂuences the biomarkers of insulin sensitivity and glu-
cose uptake. First, we determined whether Ad-36 in-
creases glucose uptake in primary skeletal muscle cells
from healthy lean and diabetic subjects. Next, the effect of
Ad-36 on glucose transporters and their upstream cellular
signaling, including phosphatidylinositol 3-kinase (PI 3-ki-
nase) and its activators, was determined. Adenovirus type
2, a human adenovirus that is not adipogenic in animals
(9), was used as a negative control. The following exper-
iments showed that Ad-36 activates PI 3-kinase and in-
creases glucose uptake in nondiabetic and diabetic human
skeletal muscle (HSKM) cells. Activation of PI 3-kinase by
Ad-36 requires Ras signaling but not insulin signaling
pathway.
RESEARCH DESIGN AND METHODS
BSA and the protease inhibitors, phenylmethylsulfonyl ﬂuoride, and all other
reagent grade chemicals were purchased from Sigma (St. Louis, MO). Skeletal
muscle cell growth medium (SkGM) (Cambrex, Walkersville, MD); fetal
bovine serum (FBS) (Hyclone, Logan, UT); GLUT1 antibody (Chemicon,
Temecula, CA); monoclonal GLUT4 (1F8) antibody (R&D Systems, Minneap-
olis, MN); polyclonal antibody to insulin receptor -subunit (IR) (Santa Cruz
Biotechnology, Santa Cruz, CA); secondary horseradish peroxidase–conju-
gated antibody, protein A Sepharose, and chemiluminescence reagents (ECL
kit) (Amersham, Arlington, IL); nitrocellulose membrane, electrophoresis
equipment, Western blotting reagents, and protein assay kit (Bio-Rad, Her-
cules, CA); anti-p85, phosphotyrosine, insulin receptor substrate-1 (IRS-1),
IRS-2, and Ras polyclonal antibodies and pKD-Ras-v1 plasmid or pKD-neg
control-v1 plasmid (catalog no. 62-214 or 62-002, respectively; Upstate Bio-
technology, Lake Placid, NY); and [
3H]2-deoxy-D-glucose and [
32P]ATP (NEN
Life Science, Boston, MA) were purchased.
Effect of Ad-36 or Ad-2 on in vitro glucose uptake by HSKM cells obtained
from diabetic and nondiabetic human volunteers was determined. Next, the
effect of the viruses on GLUT1 and GLUT4 abundance and membrane
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DIABETES, VOL. 57, JULY 2008 1805translocation and PI 3-kinase, Ras, and insulin signaling pathways was
determined. Finally, by attenuating Ras with RNAi, we tested the hypothesis
that Ad-36 increases glucose uptake in HSKM cells by activating PI 3-kinase
via Ras signaling. The individual assays are described in details as follows.
Isolation and culture of HSKM cells. Cells were isolated from the vastus
lateralis muscle biopsy and grown as described previously (8). Protocol to
obtain muscle biopsies was approved by the human investigations committee
of the Pennington Biomedical Research Center. Brieﬂy, muscle biopsies were
obtained with a needle from the vastus lateralis muscle from six healthy lean
men (age 31.8  4.3 years; BMI 23.2  1.04 kg/m
2; mean  SE) and six men
with type 2 diabetes (age 62.3  2.8 years; BMI 33.5  3.8 kg/m
2; mean  SE).
Approximately 50 mg muscle tissue was minced with surgical scissors and
digested by 0.55% trypsin and 2.21 mmol/l EDTA with constant shaking at
37°C. After centrifugation to remove fat and debris, myoblasts were grown in
monolayer culture in SkGM with 10% (vol/vol) FBS, 1% (vol/vol) antibiotics
(10,000 units/ml penicillin G and 10 mg/ml streptomycin), 2 mmol/l glutamine,
and 25 mmol/l HEPES (pH 7.4).
Virus preparation. Ad-2 and Ad-36 viral stocks were prepared by propaga-
tion of American Type Culture Collection (ATCC; catalog numbers VR846 and
VR913, respectively) viral stocks in ATCC A549 cells (catalog number
CCL185) as described previously (10). Viral titers (plaque-forming units
[PFU]) were determined by plaque assay (11), and cell inoculations were
expressed as PFU/cell.
Infection of HSKM cells with Ad-2 and Ad-36. Cells were maintained in
SkGM medium (Cambrex) with 10% FBS. Antibiotic was removed before
Ad-36 infection. Unless otherwise indicated in ﬁgure legends, 80% conﬂuent
HSKM cells were inoculated with Ad-36 or Ad-2 at a dose of 3.8 PFU/cell. After
1 h, viruses were removed, cultures were washed, and complete medium was
added. Successful infection was ascertained by determining expressions of
respective viral genes (E4 orf-1) by quantitative RT-PCR and by expressions of
viral proteins in the appropriate groups.
Immunoﬂuorescence. HSKM cells were grown on chamber slides (Lab-
Tek) to 70–80% conﬂuency, serum starved overnight, and infected with
Ad-36 or Ad-2 (3.8 PFU/cell). After 5 days, the cells were ﬁxed in 4%
paraformaldehyde and processed for immunoﬂuorescence. Ad-36 and Ad-2
viral proteins were identiﬁed using anti–Ad-36 rabbit polyclonal antibodies
and rabbit polyclonal anti–Ad-2 antiserum, respectively. Secondary anti-
bodies were goat anti-rabbit Alexaﬂuor 594 (Invitrogen). Slides were
mounted in ProLong Gold antifade reagent with DAPI (Invitrogen). Images
were acquired on a Zeiss Axioplan 2 (Everest) using LD Plan Neoﬂuar 20
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FIG. 1. Expression of Ad-2 and Ad-36 genes and proteins in HSKM cells. A: Effect of Ad-36 dose on Ad-36 E4 orf1 gene expression on day 6 after
infection. Ad-36 E4 orf1 expression was not detected in control and Ad-2–infected cells. B: Effect of Ad-2 dose on Ad-2 E4 orf1 gene expression
on day 6 after infection. Ad-2 E4 orf1 expression was not detected in control and Ad-36–infected cells. C: The time course of Ad-36 E4 orf1 gene
expression in Ad-36–infected cells (3.8 PFU/cell). All E4 orf-1 gene expressions were normalized to -actin and expressed as nanograms mRNA.
HSKM cultures from lean, insulin-sensitive donors were used. Measurements were performed in three experiments, and data are presented as
means  SE. D: HSKM cells were infected with Ad-36 or Ad-2 (3.8 PFU/cell) and processed for immunoﬂuorescence 5 days later. Ad-36 and Ad-2
viral particles were identiﬁed using anti-Ad36 rabbit polyclonal antibodies and rabbit polyclonal anti–Ad-2 antiserum, respectively. Nuclei were
stained with DAPI. i and ii show cells expressing Ad-2 or Ad-36 proteins, respectively, and iii and iv show DAPI-stained nuclei. v and vi show 20
images of cells expressing Ad2 or Ad36 proteins, respectively.
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1806 DIABETES, VOL. 57, JULY 2008objective and Photometrics Cool Snap HQ camera. All images were
processed using Image J software (National Institutes of Health).
Ras siRNA vector transfections. Three days after Ad-36 infection of HSKM
cells, Ras siRNA transfections were performed using pKD-Ras-v1 vector or
pKD-neg control-v1 vector at 2 and 4 l/ml FuGENE HD transfection reagent
from Roche (Indianapolis, IN). The efﬁciency 80% of Ras knockdown was
conﬁrmed by quantitative RT-PCR.
Quantitative RT-PCR analysis. Conﬂuent HSKM cells were infected with
Ad-36, Ad-2, or medium. Total RNA was isolated with TRIzol reagent (Invitro-
gen) according to the manufacturer’s protocol and further puriﬁed by RNeasy
Mini kit from Qiagen (Valencia, CA). The sequences of the speciﬁc primers
obtained from IDT (San Diego, CA) were as follows: Ad-36 E4 orf-1, 5-GGC
ATACTAACCCAGTCCGATG-3 (forward) and 5-AATCACTCTCTCCAGCAGC
AGG-3 (reverse); Ad-2 E4 orf-1, 5-CCTAGGCAGGAGGGTTTTTC-3 (forward)
and 5-ATAGCCCGGGGGAATACATA-3 (reverse); Human GLUT1 (SLC2A1,
GenBank accession number NM_006516), 5-GCGGAATTCAATGCTGATGAT-3
(forward) and 5-CAGTTTCGAGAAGCCCATGAG-3 (reverse); and Human
GLUT4 (SLC2A4, GenBank accession number NM_001042), 5-CGTGGGCGG
CATGATT-3 (forward) and 5-CCAGCATGGCCCTTTTCC-3 (reverse).
Gene expressions were determined using ABI PRISM 7700 sequence
detector (Applied Biosystems) and a SYBR green detection system (Bio-Rad).
A standard was generated using cDNA pooled from experimental samples.
Relative expression levels were determined by normalization to -actin and
expressed as arbitrary units.
2-Deoxy-D-glucose uptake. HSKM cells were infected with Ad-36 or Ad-2 as
described above. At day 5 after infection, the cells were incubated overnight
in serum-free medium. Saline or insulin (100 nmol/l) was added after 14 h of
serum starvation during the last 15 min of incubation. Cells were washed
twice using PBS, and glucose uptake was determined as described by Klip et
al. (12). Brieﬂy, muscle cells were cultured in 24-well plates at 5  10
5
cells/well in SkMG medium containing 5 mmol/l glucose and 2% calf serum for
24 h at 37°C. Culture medium was replaced with serum-free medium and
glucose- and pyruvate-free skeletal muscle cell basal medium (no growth
factors) containing 10 Ci/ml [
3H]2-deoxy-D-glucose 500 l/well (Perkin Elmer
Life Sciences, Boston, MA). The glucose uptake was assessed with or without
10 mol/l cytochalasin B in KRPH. Plates were incubated for 5 min at room
temperature. After washing three times with cold PBS, the cells were lysed
with 500 l/well 0.2 N NaOH for 15 min. A total of 400 l cell lysate was
transferred to scintillation vials, and the radioactivity was determined by
scintillation counting. All assays were performed in triplicate in HSKM cells in
three separate experiments.
Preparation of muscle plasma membrane and subcellular fractions.
GLUT4 protein content in the muscle plasma membrane, low-density micro-
some (LDM), and high-density microsome (HDM) was determined at day 6
after Ad-36 infection with or without insulin stimulation in HSKM cells from
lean, insulin-sensitive donors. Muscle cell plasma and subcellular fractions
were obtained as described by Cushman et al. (13). Brieﬂy, on day 6 after
inoculation with Ad-36, Ad-2, or medium, muscle cells treated with 0 or 100
nmol/l insulin for 20 min were homogenized in 2.5 volume Lysis buffer (50
HEPES, 150 mmol/l NaCl, 10 mmol/l EDTA, 10 mmol/l Na4PH2O7, 100 mmol/l
NaF, 2 mmol/l vanadate, 0.5 mmol/l phenylmethylsulfonyl ﬂuoride, and 100
IU/ml trasylol, pH 7.4, containing 250 mmol/l sucrose) by 10 strokes in a PRO
200 homogenizer (PRO Scientiﬁc, Oxford, CT). The homogenates were
centrifuged at 16,000g at 4°C for 20 min. The resulting pellets, consisting of
membranes, nuclei, and mitochondria, were resuspended in the same buffer
and centrifuged using Beckman ultracentrifuge TL-100 (Beckman, Fullerton,
CA) with TLA 100.3 rotor at 100,000g for 60 min on a sucrose cushion (38%
[wt/wt]) to separate the nuclei/mitochondria from membranes. The plasma
membranes between the two layers were collected by centrifugation at
210,000g for 60 min. The 16,000g supernatants contained cytosolic proteins,
HDMs, and LDMs. HDMs and LDMs were collected by ultracentrifugation at
400,000g for 45 min. All the centrifugations were performed at 4°C.
Western blot analysis. Western blot assays were conducted as previously
described (14). Membranes were incubated with polyclonal or monoclonal
antibodies that recognize IRS-1, IRS-2, IR, PI 3-kinase, protein kinase B
(PKB)-p, Ras, GLUT1,o rGLUT4 and -actin antibodies. Followed by
secondary antibody conjugation with horseradish peroxidase, signals were
detected by enhanced chemiluminescence solution. The speciﬁc bands were
quantitated with scanning densitometry, and the data were normalized to
-actin levels.
Total PI 3-kinase and IRS-1– or IRS-2–associated PI 3-kinase activity
assays. A total of 500 g protein was immunoprecipitated with 3 gP I
3-kinase p85, IRS-1, or IRS-2 polyclonal antibodies to determine PI 3-kinase or
IRS-1– or IRS-2–associated PI 3-kinase activity as previously described
(15,16). The PI 3-kinase phosphate product was visualized by autoradiography
and quantitated by scanning densitometry.
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FIG. 2. 2-Deoxy-D-glucose uptake assays in Ad-2– or Ad-36–infected
HSKM cells. Human muscle cells were grown in 24-well plates to 80% of
conﬂuence in SkGM medium with 10% FBS, 10 units/ml penicillin, and
10 g/ml streptomycin sulfate. Cells were infected with medium (con-
trol) or varying doses of Ad-2 or Ad-36 for 60 min. On day 5 after
infection, 2-deoxy-D-glucose (0.2 Ci/ml [1,2-
3H]2-deoxy-D-glucose) up-
take was determined as described in RESEARCH DESIGN AND METHODS.
Means  SE of three experiments are shown. A: Basal or insulin-
stimulated glucose uptake in Ad-2–infected HSKM cells from insulin-
sensitive, lean healthy donor. #P < 0.05, insulin-stimulated vs. basal. B:
Basal or insulin-stimulated glucose uptake in Ad-36–infected HSKM
cells from insulin-sensitive, lean healthy donor in response to Ad-36
infection. #P < 0.05, insulin stimulation vs. basal status. **P < 0.01 and
***P < 0.001, Ad-36 vs. respective uninfected controls. C: Basal or
insulin-stimulated glucose uptake by HSKM cells from insulin-resistant
(type 2 diabetic) donor in response to Ad36 infection. **P < 0.01 and
***P < 0.001, Ad-36 vs. respective uninfected controls.
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FIG. 3. Effect of Ad-36 on gene expression and proteins of GLUT1 and
GLUT4 in HSKM cells. A and B: Time course studies show increases in
GLUT1 and GLUT4 gene expression in response to Ad-36 infection (3.8
PFU/cell). Relative gene expressions were normalized to -actin levels
and expressed in arbitrary units as fold change compared with unin-
fected controls. Gene expression measurements were performed in
three experiments, and data presented as means  SE. *P < 0.05, **P <
0.01, ***P < 0.001, Ad-36–infected vs. uninfected control. C: Western
blot analysis of GLUT1 and GLUT4 protein abundance in whole lysates
of HSKM cells from insulin-sensitive, lean donor at day 6 after infec-
tion with Ad-36, Ad-2, or the uninfected control. D: Western blot
analysis. GLUT4 protein content in the muscle plasma membrane (PM),
LDM, and HDM was determined at day 6 after Ad-36 infection with or
without 100 nmol/l insulin stimulation in HSKM cells from lean,
insulin-sensitive donors as described in RESEARCH DESIGN AND METHODS.
The experiments were performed in triplicate. #P < 0.05, insulin-
stimulated vs. basal condition. **P < 0.01 and ***P < 0.001, Ad-36 vs.
respective uninfected controls.
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differences in groups were determined by unpaired Student’s t test. A P value
0.05 was considered signiﬁcant.
RESULTS
Ad-36 and Ad-2 infect HSKM cells efﬁciently. Pres-
ence of viral mRNA is evidence of successful viral entry
and initiation of viral replication process in a cell. Ad-36
and Ad-2 successfully infected the cells as indicated by the
increase in their respective E4 orf-1 gene expressions in a
dose- and time-dependent manner (Fig. 1A–C).
Although the HSKM cells support viral mRNA expres-
sion, they do not show cytopathic effect in response to
Ad-2 or Ad-36, which makes it difﬁcult to determine
relative efﬁciency of infection of HSKM cells by the two
viruses. By using the same viral dose determined as PFU
per cell, we observed a ﬁvefold increase in viral mRNA
expression between 1.9 and 7.6 PFU/cell for both viruses
(Fig. 1A and B), suggestive of a comparable level of
infection by the two viruses. Moreover, Ad36 and Ad2
express viral proteins in HSKM cells and the distribution
of the infected cells 5 days after infection appears similar
for the two viruses (Fig. 1D). Collectively, these results
suggest that HSKM cells can be successfully infected with
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FIG. 4. Increased PI 3-kinase (3K) activity in response to Ad-36 infection is not associated with IRS-1 or IRS-2. HSKM cells from lean subjects
were used. Measurements were performed in triplicate experiments, and data are presented as means  SE. A: Western blot analysis for IRS-1,
IRS-2, IR, and p85 (PI 3-kinase) protein abundance in a virus dose-response study on day 6 after infection. -Actin was used as a loading control.
B: Immunoprecipitation (IP) with IRS-1 antibodies followed by Western blot analysis for IRS-1 phosphorylation and IRS-1 on day 6 after Ad-2 or
Ad-36 infection (3.8 PFU/cell), with or without insulin stimulation. C: Total PI 3-kinase activity was measured at day 6 after Ad-36 or Ad-2
infection with or without insulin stimulation (100 nmol/l) and expressed as percentage of control. *P < 0.05 and **P < 0.01, Ad-36 vs. respective
uninfected controls. D and E: IRS-1– or IRS-2–associated PI 3-kinase activities were measured, respectively, at day 6 after Ad-36 infection at
varying doses and with or without insulin stimulation. Data are expressed as percentage of control. **P < 0.01 and ***P < 0.001, Ad-36 vs.
respective uninfected controls.
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relatively similar for the two viruses.
Ad-36 induces robust increase in glucose uptake in
HSKM cells of diabetic and nondiabetic subjects.
Ad-36, but not Ad-2, signiﬁcantly increased [
3H]2-deoxy-D-
glucose uptake under basal and insulin-stimulated condi-
tions in HSKM cells obtained from nondiabetic subjects
(Fig. 2A and B). Insulin stimulation signiﬁcantly increased
glucose uptake in uninfected control cells, but insulin
could not enhance it further in the presence of the viruses.
Insulin-stimulated glucose uptake increased 70, 14, and
20% in the control and 3.8 and 7.6 PFU/cell of Ad-36
infection, respectively, compared with their corresponding
basal glucose uptakes (Fig. 2B). As expected, diabetic
muscle cells had much lower glucose uptake compared
with that of healthy lean subjects and the basal and
insulin-stimulated glucose uptake did not differ signiﬁ-
cantly. Although HSKM cells from diabetic subjects were
less responsive to glucose uptake (Fig. 2C), Ad-36 signiﬁ-
cantly increased 2D-glucose uptake in an insulin-indepen-
dent manner.
Ad-36 increases GLUT1 and GLUT4 gene expression
and protein abundance. Glucose uptake in skeletal
muscle is dependent on glucose transporter proteins,
GLUT1 and GLUT4, of which the latter is regulated by
insulin. In HSKM cells, Ad-36 infection signiﬁcantly in-
creased GLUT1 and GLUT4 gene expressions in a time-
dependent manner (Fig. 3A and B) and protein abundance
in a dose-responsive manner (Fig. 3C), whereas Ad-2
infection did not affect protein levels of the glucose
transporters (Fig. 3C). Because the translocation of glu-
cose transporters to cell membrane is required for glucose
uptake, protein abundance of GLUT4 in muscle cell mem-
brane fractions was determined (Fig. 3D). As expected,
insulin increased GLUT4 abundance in plasma membrane
fractions, indicating its translocation to the membrane.
GLUT4 translocation to plasma membrane was also en-
hanced by Ad-36 but not by Ad-2. However, insulin could
not enhance Ad-36–induced membrane translocation of
the glucose transporters, suggesting that Ad-36 impaired
the ability of insulin to stimulate glucose uptake in the
muscle cells (Fig. 3D). Ad-2 also appears to block insulin-
induced translocation of GLUT4 by unknown mechanism.
Ad-36–enhanced activation of PI 3-kinase is not via
the insulin receptor signaling pathway. Western blot
analyses for IRS-1, IRS-2, IR, and PI 3-kinase in Ad-36–
infected muscle cells show that Ad-36 reduced IRS-2
protein abundance at a dose of 3.8 PFU/cell but greatly
increased PI 3-kinase protein in a dose-responsive manner
(Fig. 4A). Ad-36 slightly increased basal IRS-1 tyrosine
phosphorylation but dramatically decreased insulin-stim-
ulated IRS-1 tyrosine phosphorylation without affecting
IRS-1 protein abundance (Fig. 4B), whereas Ad-2 mildly
reduced insulin-stimulated IRS-1 phosphorylation in the
muscle cells (Fig. 4B).
Translocation of GLUT4 to cell membrane requires PI
3-kinase activation. Because of greater translocation of the
glucose transporter in Ad-36–infected HSKM cells, we
predicted and observed signiﬁcantly greater PI 3-kinase
activation by Ad-36 infection in basal conditions, which
was further enhanced by insulin (Fig. 4C), whereas Ad-2
infection signiﬁcantly reduced insulin-stimulated PI
3-kinase activation (Fig. 4C).
As its key activator, insulin activates PI 3-kinase via the
insulin receptor signaling pathway involving the interac-
tion of IRS-1 and IRS-2 with PI 3-kinase. Although insulin
enhanced Ad-36–induced PI 3-kinase activity, it appears
to bypass the signaling pathway in the presence of the
virus. In fact, without altering IRS-1 and IR protein
abundance (Fig. 4A), Ad-36 signiﬁcantly decreased IRS-1–
or IRS-2–associated PI 3-kinase activities in response to
insulin (Fig. 4D and E). Decrease in insulin-stimulated
phosphorylation of IRS-1 in presence of Ad-36 (Fig. 4B)
further suggests the use of another pathway by insulin to
activate PI 3-kinase in the presence of the virus. Next, we
investigated the role of Ras in Ad-36–induced PI 3-kinase
activation.
Ad-36 infection increased Ras protein abundance in
HSKM cells. Ras signaling activates PI 3-kinase (17),
which is also a pathway used by human adenovirus type 9
for PI 3-kinase activation (18). Therefore, Ras signaling
was a candidate pathway for activation of PI 3-kinase by
Ad-36. Ad-36, but not Ad-2, increased Ras, GLUT1, and
GLUT4 protein abundance and PKB/Akt phosphorylation
in the whole-cell lysates of HSKM cells obtained from
nondiabetic and diabetic subjects (Fig. 5).
Ad-36 enhances PI 3-kinase activity and glucose up-
take in a Ras-dependent manner. Ad-36 infection in-
creased Ras mRNA expression in HSKM cells (Fig. 6A).
Ras siRNA transfection reduced Ras, PI 3-kinase protein
abundance, and phospho-Akt levels and attenuated Ad-36–
induced increase in GLUT4 protein abundance in a time-
dependent manner but did not affect GLUT1 abundance
(Fig. 6B). Attenuation of Ras expression also abrogated
Ad-36–induced PI 3-kinase activation (Fig. 6C) and glu-
cose uptake in the muscle cells (Fig. 6D). These results
show that Ad-36 increases glucose uptake in HSKM cells
partially by Ras-mediated PI 3-kinase signaling pathway.
DISCUSSION
In basal condition, Ad-36 infection nearly doubled and
tripled glucose uptake in diabetic and lean subjects, re-
spectively (Fig. 2A and B), and doubled PI 3-kinase activity
(Fig. 4C). By activating PI 3-kinase via Ras, a known
activator of PI 3-kinase (18–20), and by increasing mem-
brane translocation of the glucose transporters, Ad-36
increases glucose uptake in HSKM cells independent of
insulin signaling. Ad-36 increased GLUT1 protein abun-
GLUT4 
GLUT1 
Virus              -            Ad-2      Ad-36          -            Ad-2      Ad-36 
Subjects           Non-diabetic lean                   Type 2 diabetic   
Virus dose (3.8 PFU/cell) 
Ras 
Akt-p 
β-actin 
FIG. 5. Ad-36 increases Ras protein abundance, Akt activation, and
GLUT1 and GLUT4 protein abundance in HSKM cells from lean and
diabetic subjects. Western blot analysis of HSKM cells on day 6 after
infection with or without Ad-36 or Ad-2. -Actin was used as a loading
control. Western blots are representative of three experiments.
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dependent glucose uptake.
Although the insulin signaling pathway is a well-known
activator of PI 3-kinase, Ad-36 induced robust activation of
PI 3-kinase without IRS-1 or IRS-2 activation. Ad-36–
induced reduction in IRS-1 or IRS-2 activity may be due to
inhibitory feedback from increased cellular glucose (21),
from the activation of PI 3-kinase itself (22), or from
activation of p38 MAPK (23), a kinase commonly induced
by adenoviruses (24). In addition, whether Ad-36 directly
impairs tyrosine phosphorylation of IRSs remains to be
investigated. Even without IRS-1 or IRS-2 activation, insu-
lin did enhance PI 3-kinase activation induced by Ad-36,
suggesting the participation of an IRS-independent path-
way. It is likely that insulin stimulated tyrosine phosphor-
ylation of insulin receptor, which activated PI 3-kinase via
Ras and independent of IRS activation (25). It is unknown
why the increased PI 3-kinase activation by insulin in the
presence of Ad-36 did not further enhance glucose uptake
induced by the virus. Similarly, Ad-2 appears to block
insulin-stimulated translocation of GLUT4 translocation to
the membrane by an unknown mechanism, which may
contribute to a lack of insulin response on glucose uptake
in the presence of Ad-2 infection. Thus, Ad-36–induced
glucose uptake was independent of insulin but partially
depended on Ad-36–enhanced Ras-mediated PI 3-kinase
and PKB signaling pathway.
Ad-36 elevated Ras protein abundance in a viral dose-
responsive manner, and the effects of Ad-36 on activation
of PI 3-kinase, GLUT4 abundance, and glucose uptake
were attenuated by inhibition of Ras expression. Ras is an
important mediator of anti-apoptotic signals induced by
survival factors and promotes survival of many cell sys-
tems by activating the PI 3-kinase/PKB pathway (26,27).
Role of Ras in increased glucose uptake has been previ-
ously reported (28), and other adenoviruses have been
reported to activate Ras or PI 3-kinase (18,29,30). How-
ever, effect of these adenoviruses on glucose uptake by
HSKM cells is unknown.
In summary, Ad-36 infection increased glucose uptake
by HSKM cells by increasing GLUT1 and GLUT4 gene
expression and protein abundance, which appears to be
mediated via Ras-activated PI 3-kinase pathway and inde-
pendent of insulin signaling (Fig. 7). Considering the major
contribution of skeletal muscle to glucose disposal, mod-
ulating its ability to uptake glucose may have a major
impact on systemic glycemic control. Particularly, the
unique and robust ability of Ad-36 to enhance skeletal
muscle glucose uptake in an insulin signaling–independent
manner is of great interest and may be exploited for
developing new drug targets for insulin resistance and
type 1 and type 2 diabetes. Future experiments should
identify the viral gene(s) responsible and further elucidate
the molecular and cellular pathways involved in Ad-36–
induced glucose uptake, such as the AMPK pathway, to
determine therapeutic targets that mimic the effect.
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FIG. 6. Ras siRNA transfection reduces PI 3-kinase (3K), Akt-p,
GLUT4, and glucose uptake in Ad-36–infected HSKM cells. A: Ras gene
expression was determined on day 6 after inoculation with Ad-36 (3.8
PFU/cell) or medium (control) in HSKM cells of lean subjects. ***P <
0.001 Ad-36 vs. control. B and D: HSKM cultures from lean, insulin-
sensitive donors were inoculated with Ad-36 (3.8 PFU/cell) or medium
(control). On day 3 after infection, cells were transfected with a 2
g/ml Ras siRNA and Ras-negative control vectors, respectively. Three
days after transfection, assays were conducted in three experiments,
and data are presented as means  SE. *P < 0.05, **P < 0.01, ***P <
0.001, Ad-36 vs. uninfected controls. ##P < 0.01, Ad-36 infection  Ras
RNAi vs. Ad-36 infection alone. B: Time course of Ad-36 infection in
HSKM with or without Ras siRNA transfection. Ras, PI 3-kinase, Akt-p,
Glut4, and Glut1 protein abundance were determined by Western blot
analysis using -actin as a loading control. C: PI 3-kinase activity was
determined on day 6 after Ad-36 infection with or without Ras siRNA or
negative control (NC) vectors. Data are expressed as fold change
compared with that of the uninfected control. D:[
3H]2-deoxy-D-glucose
uptake was determined 6 days after infection with Ad-36 with or
without Ras siRNA transfection.
Z.Q. WANG AND ASSOCIATES
DIABETES, VOL. 57, JULY 2008 1811In conclusion, our ﬁndings suggest that the increase of
glucose uptake by skeletal muscle may contribute to
better glycemic control observed in Ad-36–induced ani-
mals (5). Considering the robust effect of the virus on
glucose uptake, the cellular and viral protein interaction
should be evaluated as therapeutic targets for improving
glycemic control in humans.
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